SLC6A3 and Parkinson disease: Despite evidence for the dopaminergic losses in the substantia nigra and dorsal striatum being responsible for motor impairment in Parkinson’s disease,17,18 several previous studies with [18F]FE-PE2I PET in smaller cohorts failed to report significant associations between DAT loss and clinical motor scores.6,7,9,11 However, a recent cross-sectional study, which employed a larger cohort and consistent medication state between imaging and clinical examination did indeed report a significant association between DAT loss in putamen (and sensorimotor striatum) and clinical motor scores.10